Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase I Study of UCN-01 and Carboplatin in Patients With Advanced Solid Tumors

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase I	Treatment	Completed	18 and over	NCI	MSGCC-0143 NCI-5533, NCT00036777, 5533

Trial Description

Purpose:

UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with carboplatin may kill more tumor cells.

Phase I trial to study the effectiveness of combining UCN-01 with carboplatin in treating patients who have advanced solid tumors.

Eligibility:

• At least 18 years old
• At least 4 weeks since chemotherapy and radiation therapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive a 1-hour infusion of carboplatin followed by a 3-hour infusion of UCN-01. Treatment may be repeated every 3 weeks for up to six courses.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Greenebaum Cancer Center at University of Maryland Medical Center

Martin Edelman, MD, Protocol chair		Ph: 410-328-2703; 800-888-8823 Email: medelman@umm.edu

Registry Information
Official Title		A Phase I Study Of UCN-01 In Combination With Carboplatin In Advanced Solid Tumors
Trial Start Date		2002-04-29
Registered in ClinicalTrials.gov		NCT00036777
Date Submitted to PDQ		2002-03-06
Information Last Verified		2004-11-22
NCI Grant/Contract Number		U01-CA69854

Back to Top